Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. Kopruszinski CM, Linley JE, Thornton P, Walker AS, et al. Brain 2025 Feb 28:awae344. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kopruszinski CM, Linley JE, Thornton P, Walker AS, et al. Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. Brain 2025 Feb 28:awae344. doi: 10.1093.
PMID: 40036725